TrialInternational journal of chronic obstructive pulmonary disease2012

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Donald P Tashkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.